FORM
6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
Dated
October 4, 2007
BIOMIRA
INC.
(Translation
of registrant’s name into English)
Edmonton
Research Park
2011-94
Street, Edmonton, Alberta Canada T6N1H1
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
|
Form
20-F
x
(for
past years ending in calendar year 1996)
|
Form
40-F
x
(commencing
in calendar year 1997)
|
Indicate
by check mark whether the registrant by furnishing the information contained
in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
If
“Yes” is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
EXPLANATORY
NOTE
On
September 12, 2007, Biomira Inc. (“Biomira”) filed with the System for
Electronic Document Analysis and Retrieval in Canada (“SEDAR”) a News Release
related to the announcement that the Board of Directors of Biomira has approved
a proposal to change its jurisdiction of incorporation from the federal
jurisdiction of Canada to the State of Delaware in the United States of America
through a plan of arrangement. A copy of the News Release is attached
to this report as Exhibit 1.
On
September 14, 2007, Biomira filed with SEDAR a transcript of a conference
call/webcast made to members of the financial analyst community and
investors. A copy of the transcript is attached to this report as
Exhibit 2.
On
October 1, 2007, Biomira filed with SEDAR a News Release related to the
announcement that as part of its plan to change its jurisdiction of
incorporation to the State of Delaware the company plans to change its name
to
Oncothyreon Inc. A copy of the News Release is attached to this
report as Exhibit 3.
On
October 3, 2007, Biomira filed with SEDAR a News Release related to the
announcement that Robert Kirkman, M.D., Biomira’s President and Chief Executive
Officer, is scheduled to present at the BIO InvestorForum 2007. A
copy of the News Release is attached to this report as Exhibit
4.
EXHIBIT
INDEX
|
|
|
|
|
|
|
|
|
1
|
|
News
Release (incorporated by reference from Biomira’s Rule 425 submission
filed with the Securities and Exchange Commission on September
12,
2007).
|
|
|
|
|
|
2
|
|
Transcript
of conference call/webcast (incorporated by reference from Biomira’s Rule
425 submission filed with the Securities and Exchange Commission
on
September 12, 2007).
|
|
|
|
|
|
3
|
|
News
Release (incorporated by reference from Biomira’s Rule 425 submission
filed with the Securities and Exchange Commission on September
27,
2007).
|
|
|
|
|
|
4
|
|
News
Release (incorporated by reference from Biomira’s Rule 425 submission
filed with the Securities and Exchange Commission on October 3,
2007).
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
|
BIOMIRA
INC.
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
Date:
October 4, 2007
|
By:
|
/s/
Edward A. Taylor
|
|
|
|
Edward
A. Taylor
|
|
|
|
Vice
President, Finance & Administration and Chief Financial
Officer
|
|
|
|
|
